期刊文献+

高敏C反应蛋白在双胍类和磺脲类治疗后的糖尿病患者中的变化

Effect of metformin and sulfonylurea on high sensitive C-reactive protein level in type 2 diabetic patients
下载PDF
导出
摘要 目的探讨炎症因子高敏C反应蛋白(hs-CRP)在使用双胍类和磺脲类联合治疗12周后的2型糖尿病患者中的变化。方法采用免疫比浊法定量检测48例2型糖尿病患者治疗前后hs-CRP的水平,酶法检测空腹血糖(FBG)、血脂,高效液相法检测糖化血红蛋白(HbA1c),比较其治疗前后的变化。结果2型糖尿病患者治疗前后体质量指数(25.62±2.92)vs(25.09±2.98),腰围(85.73±8.66)cm vs(84.75±8.72)cm,FBG(7.92±1.43)mmol/L vs(5.96±1.31)mmol/L,总胆固醇(5.63±1.08)mmol/L vs(4.98±0.79)mmol/L,甘油三酯(2.19±2.09)mmol/L vs(1.58±0.96)mmol/L,低密度脂蛋白胆固醇(3.29±1.17)mmol/L vs(2.91±0.59)mmol/L,hs-CRP(1.66±0.93)mg/L vs(1.20±0.86)mg/L,HbA1c(7.29±1.26)%vs(6.79±0.96)%;上述指标治疗后较治疗前明显下降,其差异有统计学意义(均P<0.01)。结论2型糖尿病患者在血糖、体质量和腰围控制的同时hs-CRP水平降低,hs-CRP可作为临床医生治疗2型糖尿病及其血管并发症时疗效观察的监测指标之一。 Objective To study the effect of metformln and sulfonylurea on high sensitive C-reactive protein (hs-CRP) level in type 2 diabetic patients. Methods Hs-CRP level was determined by immuoturbidimetric method in 48 cases of type 2 diabetes treated with metformin and sulfonylurea. Also,their fasting blood glucose(FBG), blood cholesterol,glycosylated hemoglobin(1c)(HbA1c) were detected. Results Type 2 diabetes patients showed significant differences before and after treatment in body mass index(25.62±2.92) vs (25.09 ±2.98), waist circumference (85.73±8.66) cm vs (84.75±8.72) cm, FBG(7.92 ±1.43) mmol/L vs (5.96 ±1.31) mmol/L, total cholesterol (5.63±1.08) mmol/L vs (4.98±0.79) mmol/L, triglycerides (2.19±2.09) mmol/L vs (1.58±0.96) mmol/L, low-density lipoprotein cholesterol(3.29±1.17) mmol/L vs (2.91 ±0.59) mmol/L, hs-CRP(1. 66±0. 93) mg/L vs (1.20±0.86) mg/L,HbA1c(7.29±l. 26);vs (6.79±0.96)%,(all P〈0.01). Conclusion Hs-CRPlevelreduces in type 2 diabetic patients while their blood glucose, body mass index and waist circumference are controlled. Hs-CRP can be an effective factor in the evaluation of treatments for type 2 diabetes.
出处 《临床荟萃》 CAS 北大核心 2007年第19期1386-1388,共3页 Clinical Focus
关键词 糖尿病 2型 C反应蛋白质 二甲双胍 格列吡嗪 diabetes mellitus, type 2 C-reactive protein metformin glipizide
  • 相关文献

参考文献10

  • 1何冰.急性时相蛋白与糖尿病[J].国外医学(内分泌学分册),2003,23(1):26-29. 被引量:38
  • 2Pickup JC,Crook MA.Is type 2 diabetes mellitus a disease of innate immune system?[J].Diabetologia,1998,41 (10):1241-1248.
  • 3Ford ES.Body mass index,diabetes,and c-reactive protein among US adults[J].Diabetes Care,1999,22(2):1971-1977.
  • 4张平安 ,吴健民 ,李艳 .C-反应蛋白与2型糖尿病[J].国外医学(临床生物化学与检验学分册),2004,25(3):231-233. 被引量:37
  • 5王中心,黄一鑫.2型糖尿病大血管并发症与血清C-反应蛋白水平关系的研究[J].临床荟萃,2006,21(7):493-495. 被引量:11
  • 6Feata A,d'Agostino R Jr,Howard G,et al.Chronic subclinical inflammation as part of the insulin resistance syndrome:the Insulin Resistance Atherosclerosis Study (IRAS)[J].Circulation,2000,102 (1):42-47.
  • 7Deans KA,Sattar N."Anti-inflammatory" drugs and their effects on type 2 diabetes[J].Diabetes Technol Ther,2006,8(1):18-27.
  • 8Carter AM,Bennett CE,Bostock JA,et al.Metformin reduces C-reactive protein but not complement factor C3 in overweight patients with type 2 diabetes mellitus[J].Diabet Med,2005,22(9):1282-1284.
  • 9Akbar DH.Effect of metformin and sulfonylurea on C-reactive protein level in well-controlled type 2 diabetics with metabolic syndrome[J].Endocrine,2003,20(3):215-218.
  • 10Putz DM,Goldner WS,Bar RS,et al.Adiponectin and C-reactive protein in obesity,type 2 diabetes,and monodrug therapy[J].Metabolism,2004,53(11):1454-1461.

二级参考文献27

  • 1Koenig W,Sund M,Frohlich M,et al.C-Reactive protein,a sensitive marker of inflammation,predicts future risk of coronary heart disease in initially healthy middle-aged men:results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Diseas
  • 2Spranger J,Kroke A,Mohlig M,et al.Inflammatory cytokines and the risk to develop type 2 diabetes:results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study.Diabetes,2003,52(3):812-817.
  • 3Yudkin JS,Panahloo A,Stehouwer C,et al.The influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in Type II diabetic subjects.Diabetologia,2000,43(9):1099-1106.
  • 4Volanakis JE.Human C-reactive protein:expression,structure,and function.Mol Immunol,2001,38(2-3):189-197.
  • 5Ford ES.Body mass index,diabetes,and C-reactive protein among U.S.adults.Diabetes Care,1999,22(12):1971-1977.
  • 6Pradhan AD,Manson JE,Rifai N,et al.C-reactive protein,interleukin 6,and risk of developing type 2 diabetes mellitus.JAMA,2001,286(3):327-334.
  • 7Taniguchi A,Nagasaka S,Fukushima M,et al.C-reactive protein and insulin resistance in non-obese Japanese type 2 diabetic patients.Metabolism,2002,51(12):1578-1581.
  • 8Colwell GA.Inflammation and diabetic vascular complications.Diabetes Care,1999,22(12):1927-1928.
  • 9Woodman RJ,Watts GF,Puddey IB,et al.Leukocyte count and vascular function in Type 2 diabetic subjects with treated hypertension.Atherosclerosis,2002,163(1):175-181.
  • 10Mojiminiyi OA,Abdella N,Moussa MA,et al.Association of C-reactive protein with coronary heart disease risk factors in patients with type 2 diabetes mellitus.Diabetes Res Clin Pract,2002,58(1):37-44.

共引文献83

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部